7MM regulatory T-cell market to grow over 57% CAGR by 2034 | Healthcare Asia Magazine
Photo from Envato

7MM regulatory T-cell market to grow over 57% CAGR by 2034

Currently, no Treg-based therapies are approved.

The regulatory T-cells (Tregs) sector across the seven major markets (7MM) is projected to grow at a compound annual growth rate exceeding 57% through 2034, according to a report by DelveInsight.

The market is expected to expand as companies actively develop new regulatory T-cell therapies to address different conditions such as Lupus Nephritis, Atopic Dermatitis, Rheumatoid Arthritis, and Psoriasis.

Currently, no Treg-based therapies are approved. The first approval is anticipated in the US by 2026, which is expected to drive early market expansion.

7MM = US, Germany, France, Italy, Spain, UK, and Japan.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!